Loading stock data…
$1.23-0.04 (-3.15%)
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States.
Equillium, Inc. in the Healthcare sector is trading at $1.23 with a market capitalization of $134M. Wall Street consensus targets $8.56 (9 analysts), implying a +595.6% move over the next 12 months. The stock is currently near its 52-week low of $0.76, remaining 40.6% below its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$5.16M↑ | -$5.61M↓ | -$3.96M↑ | -$4.58M↑ | -$6.23M |
| Net Income | -$4.69M↑ | -$5.31M↓ | -$3.77M↑ | -$4.23M↑ | -$5.74M |
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinica...